GRIFOLS S A/S (NASDAQ:GRFS)‘s stock had its “hold” rating reissued by Kepler Capital Markets in a research note issued to investors on Friday, AnalystRatings.com reports.
Several other equities analysts have also weighed in on the stock. BidaskClub upgraded shares of GRIFOLS S A/S from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 10th. Zacks Investment Research lowered shares of GRIFOLS S A/S from a “buy” rating to a “hold” rating in a report on Thursday, March 12th. Banco Sabadell upgraded shares of GRIFOLS S A/S from a “sell” rating to a “buy” rating in a report on Monday, December 9th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of GRIFOLS S A/S in a report on Friday, March 6th. Finally, Citigroup lowered shares of GRIFOLS S A/S from a “buy” rating to a “neutral” rating in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $24.25.
NASDAQ:GRFS opened at $19.52 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 3.92 and a quick ratio of 2.21. The firm has a market capitalization of $13.37 billion, a price-to-earnings ratio of 21.69, a PEG ratio of 0.95 and a beta of 1.11. The company’s 50-day moving average is $21.92 and its two-hundred day moving average is $22.01. GRIFOLS S A/S has a 1-year low of $13.40 and a 1-year high of $25.73.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Featured Article: Initial Coin Offerings entail a high degree of risk
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.